Medicenna Therapeutics announced that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, which notified the Company of the delisting of its securities from the Nasdaq Capital Market as a result of the Company’s failure to comply with the US$1.00 per share minimum bid price requirement. The Company informed Nasdaq that it would not appeal the delisting decision or try to regain compliance by executing a reverse stock split. The Company’s common shares will continue to trade on the Toronto Stock Exchange.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDNA:
- Medicenna Announces Nasdaq Delisting and Cutback of Management Team
- Medicenna doses first patient in Phase 2 dose expansion of Phase 1/2 ABILITY
- Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
- Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
- Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer